Inhibikase Therapeutics, Inc.

Impacting Patient Lives by Treating Disease Where It Begins

Novel Treatments that are Inspiring Hope

We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other diseases caused by dysfunction of the Abelson Tyrosine Kinases.

Learn About Our Company

Inhibikase Therapeutics, Inc.

Understanding the Intricacies of the Mechanism of Parkinson’s Disease

A New Approach to Designing Small-molecule Kinase Inhibitors

We believe that we have a novel understanding of where and how Parkinson’s disease begins in the body, based on validated, emerging science that disrupts current beliefs about how and where the disease exists and how it is caused.

We believe we could modify the course of this neurodegenerative disease.

Explore Our Pipeline

Inhibikase Therapeutics, Inc.

Creating Disruptive Therapies for Neurodegenerative Diseases

Altering the Pathway of Disease with Our Innovative Technology

We believe that the same disease mechanism could be at work in other neurodegenerative diseases caused by a misfolded protein such as in Multiple Sytem Atrophy, Dementia with Lewy Body and Alzheimer’s disease, where we are also developing treatments that could intervene to alter the course of the disease, not just address symptoms.

Discover the Treatment Possibilities

A New Paradigm for Treating Neurodegenerative Diseases

Our robust pipeline includes multiple candidates aiming to stop and/or reverse the effects of neurodegenerative disease inside and outside the brain. These candidates were developed using our RAMP™ drug innovation and prodrug technology engines.

Explore Our Pipeline

Our Disease Modifying Strategy for Parkinson’s Disease

Our goal is to provide meaningful treatment options for patients with Parkinson’s Disease that could change the course of the disease in the body.

Watch Video

Patient Resources

Be a Part of Our Innovative Research

Are you interested in our clinical trials for Parkinson’s disease? Find out more about how to be evaluated for enrollment in our trials.

Get Involved

Recent Media

Inhibikase CEO Dr. Milton Werner - VJ Neurology Series

View More

Stock Snapshot